Diagnostic Ventures
Diagnostic Ventures is focused on advancing rapid diagnostics technology to improve patient outcomes, especially in the detection of sepsis. Their mission is to build diagnostic technology solutions for time-critical conditions, leveraging innovative approaches developed at Brigham Young University with significant funding and patents. They aim to provide fast, accurate, and affordable diagnostic tests, including a rapid sepsis test that delivers results in 1 hour, significantly faster than current methods. The company collaborates with leading researchers and healthcare professionals to tackle complex health issues and improve diagnostic capabilities.
Industries
Nr. of Employees
small (1-50)
Diagnostic Ventures
Products
Rapid sepsis diagnostic (platform combining centrifugal sample preparation and multiplex qPCR)
A diagnostic platform under development that combines centrifugal sample preparation (single-use disk) with multiplex qPCR to identify sepsis pathogens from whole blood without a culture step; the site states initial detection of five pathogenic targets with R&D to expand coverage. The product is stated to be under development and not FDA approved.
Rapid sepsis diagnostic (platform combining centrifugal sample preparation and multiplex qPCR)
A diagnostic platform under development that combines centrifugal sample preparation (single-use disk) with multiplex qPCR to identify sepsis pathogens from whole blood without a culture step; the site states initial detection of five pathogenic targets with R&D to expand coverage. The product is stated to be under development and not FDA approved.
Services
Laboratory chemical research activities supporting assay and diagnostic development.
Microscopy services used for sample characterization and research support.
Pathology services and related testing used in clinical laboratory contexts.
Provision and development of single-use centrifugal disks for blood sample processing in the diagnostic workflow.
Development and application of multiplex qPCR assays for pathogen and resistance gene detection in blood samples.
Standard clinical tests offered or referenced such as complete blood count, electrolyte panels, bilirubin, lipid profiles, glucose tolerance testing and urinalysis.
Laboratory chemical research activities supporting assay and diagnostic development.
Microscopy services used for sample characterization and research support.
Pathology services and related testing used in clinical laboratory contexts.
Provision and development of single-use centrifugal disks for blood sample processing in the diagnostic workflow.
Development and application of multiplex qPCR assays for pathogen and resistance gene detection in blood samples.
Standard clinical tests offered or referenced such as complete blood count, electrolyte panels, bilirubin, lipid profiles, glucose tolerance testing and urinalysis.
Expertise Areas
- Rapid molecular diagnostics
- Sample preparation using centrifugal microfluidics
- Multiplex qPCR assay development
- Pathogen detection from whole blood
Key Technologies
- Multiplex quantitative PCR (qPCR)
- Centrifugal microfluidic sample preparation (spinning disk)
- Single-use diagnostic consumables
- Molecular pathogen detection
News & Updates
Global statistics highlighting the impact of sepsis, including 50 million infections and 11 million deaths annually.
Information about the company's innovative sepsis detection technology and its benefits.
Originally funded by a $5.2M NIH grant, with patents awarded and pending for their diagnostic processes.
Global statistics highlighting the impact of sepsis, including 50 million infections and 11 million deaths annually.
Information about the company's innovative sepsis detection technology and its benefits.
Originally funded by a $5.2M NIH grant, with patents awarded and pending for their diagnostic processes.